Quantcast

Latest Soliris Stories

2014-06-03 23:05:30

On June 2, the FDA announced that certain lots of Soliris (eculizumab) Concentrated Solution for IV Infusion, by Alexion, are recalled due to visible particulates. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. (PRWEB) June 03, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Soliris (eculizumab). The FDA...

2011-02-28 04:59:00

Canadian Association of PNH Patients raises the volume on plea for access to life-saving treatment To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-association-of-pnh-patients/patients-with-rare-blood-disease-turn-to-social-media TORONTO, Feb. 28 /PRNewswire/ - With so few people affected by rare diseases, how does a group of less than 90 patients across Canada make their voices heardon a life-and-death issue such as access to treatment? Barry...

2009-01-05 05:30:00

Alexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents known as the Queen et al....

2008-12-09 06:00:00

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with PNH. A separate study found that Soliris was observed to reduce indicators of pulmonary artery hypertension (PAH) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a new...

2008-12-08 12:30:00

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia...

2008-12-07 12:00:00

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a limited number of patients with two other rare and severe complement-mediated diseases treated outside of a clinical trial, according to patient cases presented today at the 50th Annual Meeting of...

2008-11-10 15:00:07

CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with eculizumab in patients with two other rare diseases (Atypical Hemolytic Uremic Syndrome and Cold Agglutinin Disease). Abstracts will be presented...

2008-10-23 06:00:27

CHESHIRE, Conn., Oct. 23 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company," Nasdaq: ALXN) today announced financial results for the quarter ended September 30, 2008. Third Quarter 2008 Financial Results: For the three months ended September 30, 2008, Alexion reported total revenues of $76.5 million from net product sales of Soliris(R) (eculizumab), compared to total revenues of $21.8 million for the same period in 2007. The Q3 2008 revenues consisted of...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related